Sodium phosphate (oral)

Generic name
Sodium phosphate (oral)
Brand name
ATC Code
A12CX

Sodium phosphate (oral)

Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Pharmacokinetics in children

No information

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

Available formulations

No information is present at this moment.

Dosages

Hypophosphataemia
  • Oral
    • 0 years up to 18 years
      • 1 - 3 mmol/kg/day in 3 - 4 doses. Max: 30 mmol/day.
      • Dose depending on the serum phosphate concentration

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects

No information is present at this moment.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

Caution is needed in young children.

When phosphate is supplemented in children, sodium dihydrogen phosphate is preferred instead of disodium dihydrogen phosphate and/or potassium salts in order to keep the sodium and potassium exposure as low as possible

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

MINERAL SUPPLEMENTS

This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.

CALCIUM
A12AA04
A12AX
A12AA06
POTASSIUM
A12BA30
A12BA01
A12BA02
OTHER MINERAL SUPPLEMENTS
A12CC05
A12CC01
A12CC04
A12CC03
A12CC02
A12CE02
A12CA01
A12CB01

References

  1. Latta K et al., Therapeutics of X-linked hypophosphatemic rickets., Pediatr Nephrol., 1993, Dec;7(6):, 744-8
  2. UMC St. Radboud.., Indicatiegericht formularium, Versie 1.1.1.0. ., Geraadpleegd: feb 2014, http://igf.medecs.nl/Default.aspx?locatie=Umcn

Changes

Therapeutic Drug Monitoring


Overdose